Aggressive Intravenous Hydration With Lactated Ringer's Solution for Prevention of Post-ESWL Pancreatitis

• Status: Not yet recruiting
• Trial end date: 2024-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The goal of this clinical trial is to clarify whether aggressive intravenous hydration with lactated Ringer's solution could reduce the incidence of post-ESWL pancreatitis in patients with chronic pancreatitis.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Changhai Hospital

Criteria

Inclusion Criteria:

All patients with chronic pancreatitis aged between18 and 85 years who were eligible for treatment with ESWL for pancreatic stones were eligible for enrolment.

Exclusion Criteria:

1. Patients readmitted to the hospital for ESWL during the study period.

2. Acute pancreatitis in the last 3 days.

3. Signs of congestive heart failure, such as pitting edema or a New York Heart Association classification greater than class I heart failure.

4. Respiratory insufficiency (pO2 < 60 mmHg or saturation < 90% despite FiO2 of 30% or requiring mechanical ventilation).

5. Severe liver disease (cirrhosis, liver abscess).

6. Patients receiving more than 1.5 mL/kg/h or 3 L/24 h of intravenous fluids in the 24 h before ESWL.

7. Hypotension (systolic blood pressure <90 mmHg or mean arterial pressure <70 mmHg).

8. Hypo- or hypernatremia (serum Na+ levels < 130 or > 150 mmol/L).

9. Pregnancy.

10. Unwilling or unable to provide consent.